Inhibikase Therapeutics Inc Ordinary Shares IKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IKT is a good fit for your portfolio.
News
-
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
-
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
-
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
-
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
-
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
-
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
-
Inhibikase Shares Rise Premarket on FDA Orphan Designation for Risvodetinib
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.30–1.40
- 52-Week Range
- $0.79–4.35
- Bid/Ask
- $1.28 / $1.37
- Market Cap
- $8.81 Mil
- Volume/Avg
- 9,941 / 62,606
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson��s-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.inhibikase.com
Valuation
Metric
|
IKT
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
IKT
|
---|---|
Quick Ratio | 3.85 |
Current Ratio | 4.13 |
Interest Coverage | — |
Quick Ratio
IKT
Profitability
Metric
|
IKT
|
---|---|
Return on Assets (Normalized) | −85.91% |
Return on Equity (Normalized) | −100.90% |
Return on Invested Capital (Normalized) | −104.98% |
Return on Assets
IKT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nhrvxbshw | Pgg | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vlzthhdql | Tbhqmlx | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dmvgryw | Myxfvt | $107.6 Bil | |
MRNA
| Moderna Inc | Hdcvtvbq | Djnps | $47.0 Bil | |
ARGX
| argenx SE ADR | Qqwpsjbx | Xhw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wlfqrxjb | Vsvg | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wcvvtdc | Nwqbjx | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xxjqzbx | Vnqssx | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mjgwwknmn | Bgnzf | $12.7 Bil | |
INCY
| Incyte Corp | Vrxxkvscz | Bwbcfvl | $12.0 Bil |